A
Advanced BioDesign
Overcoming tumor drug resistance
About Advanced BioDesign
Advanced BioDesign is a biotechnology company specializing in the development of ALDH1 enzyme inhibitors for cancer treatment. Operating in the biosciences sector, the company collaborates with academic and industrial partners globally. Founded in 2010, Advanced BioDesign focuses on business development, innovation management, and industrial property. The company has successfully raised funds from private investors, strengthening its board and scientific committee. Its lead product, ABD 3001, targets acute myeloid leukemia (AML) and entered clinical trials in early 2023, showing a promising safety profile. Another product, ABD 0171, is being developed for solid tumors and has shown enhanced efficacy when combined with anti-PD1 therapies. Additionally, the company has developed a predictive and prognostic test to identify and stratify patients based on ALDH enzyme activity. Advanced BioDesign generates revenue through the development and commercialization of its proprietary cancer therapies and diagnostic tests.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Saint-Priest, France
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A1 investor entered at this stage
Xerys
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Advanced BioDesign on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Advanced BioDesign on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.